Illumina (NASDAQ:ILMN) Upgraded by Barclays to Equal Weight

Barclays upgraded shares of Illumina (NASDAQ:ILMN) from an underweight rating to an equal weight rating in a research note released on Tuesday, Analyst Price Targets reports. The firm currently has $412.00 price objective on the life sciences company’s stock, down from their previous price objective of $432.72.

ILMN has been the topic of a number of other reports. TheStreet lowered Illumina from a b- rating to a c rating in a research note on Wednesday, October 6th. SVB Leerink increased their target price on Illumina from $420.00 to $430.00 and gave the stock a market perform rating in a research report on Tuesday. Bank of America raised Illumina from an underperform rating to a neutral rating and set a $390.00 price objective for the company in a research report on Friday, January 7th. Robert W. Baird cut their target price on Illumina from $493.00 to $437.00 and set a neutral rating on the stock in a research note on Monday, November 8th. Finally, Citigroup cut their target price on Illumina from $450.00 to $400.00 and set a neutral rating on the stock in a research note on Thursday, January 6th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Hold and an average price target of $443.69.

ILMN opened at $405.14 on Tuesday. The firm has a market cap of $63.32 billion, a P/E ratio of 66.53, a price-to-earnings-growth ratio of 3.22 and a beta of 0.90. Illumina has a 52-week low of $341.03 and a 52-week high of $555.77. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.24 and a current ratio of 2.68. The business’s fifty day moving average is $378.55 and its 200-day moving average is $428.48.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, November 4th. The life sciences company reported $1.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.21. Illumina had a return on equity of 15.03% and a net margin of 21.17%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the company earned $1.02 earnings per share. The firm’s revenue was up 39.3% compared to the same quarter last year. On average, research analysts predict that Illumina will post 5.66 earnings per share for the current fiscal year.

In related news, SVP Charles Dadswell sold 314 shares of Illumina stock in a transaction dated Friday, October 22nd. The stock was sold at an average price of $411.00, for a total value of $129,054.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Alexander Aravanis sold 2,926 shares of Illumina stock in a transaction dated Tuesday, October 19th. The stock was sold at an average price of $411.82, for a total value of $1,204,985.32. The disclosure for this sale can be found here. Insiders sold 12,189 shares of company stock worth $5,024,576 over the last ninety days. Insiders own 0.23% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Evermay Wealth Management LLC bought a new position in Illumina in the second quarter worth approximately $26,000. Assetmark Inc. acquired a new position in shares of Illumina during the third quarter worth $26,000. Logan Capital Management Inc. increased its position in shares of Illumina by 90.7% during the third quarter. Logan Capital Management Inc. now owns 82 shares of the life sciences company’s stock worth $33,000 after purchasing an additional 39 shares in the last quarter. Activest Wealth Management acquired a new position in shares of Illumina in the 2nd quarter valued at $35,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of Illumina in the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 84.89% of the company’s stock.

About Illumina

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Further Reading: Golden Cross

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.